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The introduction of second-generation antipsychotic drugs for the treatment of schizophre-
nia has provided significant benefits for clients experiencing this disorder. While they have
been found effective in reducing psychotic symptoms, there is evidence that these drugs are
also linked with a group of side effects commonly known as the metabolic syndrome. Men-
tal health nurses are well positioned to prevent, detect and/or manage the development of
this problematic constellation of symptoms. Guidelines for practice can be useful in pre-
vention and management of the syndrome and enhance nursing care of clients who are tak-
ing second-generation antipsychotics.
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Introduction
 
The development of the newer second-generation or atyp-
ical antipsychotic drugs has provided benefits to many peo-
ple with schizophrenia. These are mainly related to their
lower risk of extrapyramidal side effects compared with
traditional antipsychotics, and their greater efficacy in
treating the negative and affective symptoms of psychoses.
However, the atypical antipsychotics have been linked to a
number of serious side effects, including obesity, hyperlip-
idaemia, type 2 diabetes mellitus and diabetic ketoacidosis.
Together, these comprise the potentially life-threatening
syndrome referred to as the metabolic syndrome (Hender-
son 
 
et al
 
. 2005).
This review article provides an overview of the meta-
bolic syndrome, its association with schizophrenia, and the
underlying mechanisms of the disorder. This article also
discusses the clinical implications of this syndrome for
mental health nurses and proposes a set of guidelines for
use by clinicians managing people with schizophrenia who
are prescribed the second-generation antipsychotic drugs.
 
Antipsychotic drugs and their use in the 
treatment of schizophrenia
 
The development of the antipsychotic drugs in the 1950s
was a major breakthrough in the treatment of schizophre-
nia, and these drugs have now become the mainstay of
treatment for the disorder. The traditional or first-
generation antipsychotics (FGAs) are clearly effective in the
treatment of the positive symptoms of psychosis such as
hallucinations and delusions. These drugs do not, however,
alleviate the negative symptoms of schizophrenia, and are
known to produce extrapyramidal side effects such as
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drug-induced Parkinsonism, dystonic reactions and akathi-
sia at clinically effective doses. These side effects can result
in distress, stigma, diminished function and failure to take
the medications as prescribed (Usher 1997; Therapeutic
Guidelines Ltd 2003; Consensus Development Conference
on Antipsychotic Drugs and Obesity and Diabetes 2004).
The second-generation antipsychotics (SGAs), on the other
hand, have fewer or no extrapyramidal side effects, are
more effective at treating the cognitive impairment and
negative and affective symptoms of the illness, and are
usually  better  tolerated  (Therapeutic  Guidelines  Ltd
2003; Consensus Development Conference on Antipsy-
chotic Drugs and Obesity and Diabetes 2004; Masand &
Mago 2005). For these and other reasons, the SGAs are
increasingly used over the FGAs in the treatment of psy-
chotic disorders, including schizophrenia (Lambert & Cas-
tle 2003). Nonetheless, the various SGAs have their own
side-effect profiles, and some have been linked to the devel-
opment of metabolic syndrome in people taking them for
the treatment of schizophrenia (Henderson 
 
et al
 
. 2005).
Numerous case reports also indicate a worsening of gly-
caemic control or new-onset diabetes, including diabetic
ketoacidosis (Chen 2005).
 
The prevalence of metabolic illnesses including 
diabetes in people with schizophrenia
 
People with schizophrenia are known to have a reduced life
expectancy of as many as 9–12 years less than the general
population, reported to be mainly due to factors such as an
increased rate of suicide and illness, as well as an increased
prevalence of type 2 diabetes and cardiovascular disease
(Lambert 
 
et al
 
. 2003; Holt 
 
et al
 
. 2004). The recognition of
a higher incidence of diabetes in individuals with schizo-
phrenia is not new. Holt 
 
et al
 
. (2004) claim that diabetes
was first linked to people with schizophrenia by Sir Henry
Maudsley in 1879, and therefore, people with schizophre-
nia were known to be affected by insulin resistance, weight
gain and type 2 diabetes long before the SGAs were avail-
able (Baptista 
 
et al
 
. 2004).
The effects of antipsychotics on metabolism and weight
gain were additionally identified in the 1960s (Baptista
 
et al
 
. 2004). Since this time, there has been increasing inter-
est in the link between antipsychotic medication, weight
gain, diabetes and the potential for metabolic syndrome.
Recognition of an association between SGAs, obesity and
diabetes is also evident (Consensus Development Confer-
ence on Antipsychotic Drugs and Obesity and Diabetes
2004). This is particularly the case with clozapine and
olanzapine, and less so with risperidone and quetiapine
(Procyshyn 
 
et al
 
. 2000; Consensus Development Confer-
ence on Antipsychotic Drugs and Obesity and Diabetes
2004). As a result, Sacks (2004) suggests that the term
‘metabolic liability’ should be considered in relation to the
link between antipsychotic drugs and metabolic syndrome,
and that a liability assessment should be considered prior
to commencing SGAs.
Limited evidence indicates that the prevalence of diabe-
tes among people with schizophrenia is 1.5–2.0 times
higher than the general population, but whether this is a
result of the illness or the treatment remains unknown. Pos-
sible explanations for the higher incidence of diabetes in
people with schizophrenia include the higher incidence of
obesity, poor diet and the effect of antipsychotic agents
(Chen 2005). People’s genetic makeup and their environ-
ment is also thought to contribute to the development of
metabolic syndrome, but it remains unclear as to why some
develop it and others do not (Lieberman 2004).
Recent studies suggest that the syndrome is increased in
people with schizophrenia (Holt 
 
et al
 
. 2004; Henderson
 
et al
 
. 2005), and in particular in those taking the SGA
drugs such as olanzapine and clozapine (Consensus Devel-
opment Conference on Antipsychotic Drugs and Obesity
and Diabetes 2004). Sacks (2004) reports the prevalence of
metabolic syndrome in people with schizophrenia to be as
high as 37%; however, Sacks (2004) cites the Ryan 
 
et al
 
.
(2003) study, which suggests there may be metabolic
abnormalities present in the person before the commence-
ment of antipsychotic medication and therefore, medica-
tion alone may not be responsible for the development of
metabolic syndrome.
Drug-induced weight gain, poor diet and a potential
association between SGAs and impaired glucose tolerance
are all reported in recent literature as potential links
between SGAs, schizophrenia and metabolic syndrome
(Taylor & McAskill 2000; Chen 2005). Furthermore,
antipsychotic drugs are thought to increase appetite and
subsequently weight gain, thus inducing metabolic anom-
alies (Baptista 
 
et al
 
. 2004).
 
The metabolic syndrome in schizophrenia
 
Metabolic syndrome is the presentation of a cluster of met-
abolic abnormalities associated with an increased risk of
cardiovascular disease. This group of abnormalities has
been frequently observed in people with schizophrenia, and
it appears that a high proportion of patients have the syn-
drome (Baptista 
 
et al
 
. 2004). The abnormalities of this
complex medical condition include dramatic weight gain,
especially abdominal or visceral obesity; diabetes (even the
incidence of acute metabolic decompensation such as dia-
betic ketoacidosis); atherogenic lipid profile [increased
low-density lipoprotein (LDL) cholesterol and triglyceride
levels, and reduced high-density lipoprotein (HDL) choles-
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terol]; and elevated blood pressure (Antai-Otong 2004;
Consensus Development Conference on Antipsychotic
Drugs and Obesity and Diabetes 2004; Holt 
 
et al
 
. 2004;
Sacks 2004). Insulin resistance is known to play a signifi-
cant role in most components of metabolic syndrome and
as a result, carbohydrate metabolism is critically disturbed
(Baptista 
 
et al
 
. 2004). Specifically, abdominal circumfer-
ence of more than 102 cm in men and 88 cm in women,
triglycerides greater than or equal to 150 mg/dL, HDL cho-
lesterol less than 40 mg/dL in men or less than 50 mg/dL in
women, a blood pressure greater than or equal to 130/
85 mmHg, and a fasting glucose greater than or equal to
100 mg/dL, defines the metabolic syndrome (Wirshing
 
et al
 
. 2003; Masand & Mago 2005).
This syndrome, recognized for many years now, has also
been called syndrome X or insulin-resistance syndrome
(Sacks 2004). Unfortunately, the signs and symptoms of the
syndrome often go unrecognized and untreated in people
with schizophrenia (Antai-Otong 2004). The causes of
metabolic syndrome are not well understood, but involve a
number of factors, including the presence of central or vis-
ceral obesity and insulin resistance, a sedentary lifestyle,
and genetic susceptibility (Sacks 2004).
 
Obesity
 
Significant weight gain is often the most obvious sign of
metabolic syndrome, and for many patients, is the most
distressing (Lieberman 2004). Drug-induced weight gain
from antipsychotics has for some time been associated with
patients’ reluctance to continue taking these medications,
which, in many situations, can lead to a higher risk of
relapse of psychotic symptoms (Taylor & McAskill 2000).
Significant weight gain is also a risk factor for diabetes
(Wirshing 
 
et al
 
. 2003), potentially increasing the risk of
metabolic syndrome.
 
Diabetes
 
Diabetes is a common chronic illness, which currently
affects 1.2 million people in Australia (Diabetes Australia
2004a). Diabetes mellitus is classified into four sub-groups,
of which drug-induced diabetes is included in the 
 
other
types of diabetes
 
 group (Diabetes Australia 2004b). Diabe-
tes has many increased risk factors, including weight gain,
age, dyslipidaemia and sedentary lifestyle. More recently,
SGA use has been linked to the increasing number of peo-
ple with schizophrenia and diabetes (Chue 2004; Consen-
sus Development Conference on Antipsychotic Drugs and
Obesity and Diabetes 2004). This link presents a number of
challenges for the person with schizophrenia, including
coping with another chronic illness, medication compliance
and increased risk of metabolic syndrome.
 
Dyslipidaemia
 
Impaired glucose tolerance and insulin resistance are
closely associated with abnormalities of lipid metabolism
(Chue 2004), and weight gain has been shown to be con-
cordant with lipid changes (Consensus Development Con-
ference on Antipsychotic Drugs and Obesity and Diabetes
2004). Clinical indicators of dyslipidaemia include ‘ele-
vated triglycerides, low high-density lipoprotein (LDL)
cholesterol, and small, dense low-density lipoprotein (LDL)
particles with normal or slightly elevated LDL cholesterol
levels’ (Ginsberg 2003, p. 31E).
Of the SGAs, clozapine and olanzapine are reported to
induce the greatest weight changes along with increases in
lipid levels (Consensus Development Conference on Antip-
sychotic Drugs and Obesity and Diabetes 2004), while ris-
peridone and quetiapine have a negative relationship to
weight gain. Ziprasidone and aripiprazole are considered
to have a neutral effect on weight gain (Baptista 
 
et al
 
.
2004). Phenothiazine treatment has been reported to
increase triglycerides and decrease cholesterol levels (Holt
 
et al
 
. 2004), while a 52-week open-label extension study
comparing aripiprazole and olanzapine found changes in
baseline fasting lipid levels, with the researchers concluding
that ‘symptom improvement was comparable with arip-
iprazole and olanzapine’ (Stock 
 
et al
 
. 2005).
 
Clinical implications and guidelines for practice
 
Given the rising incidence of metabolic syndrome and the
high associated morbidity and mortality (Lieberman 2004),
efficient strategies are needed to help prevent the develop-
ment of the condition and/or counteract its effects. Nurses
can play an important role in the prevention of metabolic
syndrome by increasing their understanding of the syn-
drome and educating the person who is being treated with
SGAs. The incidence of metabolic syndrome related to
SGAs in people with schizophrenia can be reduced by client
education, assistance with ongoing monitoring and the
detection of early indicators of metabolic syndrome (i.e.
increased weight circumference and elevated blood pres-
sure). The following discussion provides the nurse with
guidelines that can be followed to assist in the early detec-
tion and ongoing treatment of metabolic syndrome.
Table 1 provides a summary of the clinical indicators to
look for in assessment of metabolic syndrome.
Due to the increased risks for metabolic syndrome in cli-
ents with schizophrenia who are prescribed and taking
SGAs, there is a need for close monitoring of their physical
status. Mental health nurses have a pivotal role to play in
implementing this strategy. Baseline assessment should
include any personal and/or family history of diabetes, obe-
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sity, hypertension, dyslipidaemia and cardiovascular dis-
ease. Weight and height should be recorded and body mass
index calculated. Waist circumference should be taken at
the level of the umbilicus (Masand & Mago 2005). This in
itself may be an effective preventive measure, because mea-
surement of abdominal girth at an outpatient clinic, for
instance, has been noted to lead to behaviour change as
patients began to enquire about the reason for the mea-
surement and consequently changed their diet in response
to the explanation (Gupta 2004).
It is also important to obtain blood chemistries and mon-
itor fasting glucose and lipid levels prior to and at least every
3 months during treatment with SGAs (Wirshing 
 
et al
 
.
2003; Antai-Otong 2004; Gupta 2004; Lambert & Chap-
man 2004). Patients should be asked routinely whether they
have noticed any weight gain, a change in pants or belt size,
or whether they have experienced excessive thirst or
increased frequency of urination (Wirshing 
 
et al
 
. 2003).
Information and education about nutrition and physical
activity should be provided to all patients on commence-
ment of SGA medication, particularly those who are over-
weight. If patients gain 5% or more of their initial weight
or develop diabetes or dyslipidaemia after commencement
of the medication, the SGA may need to be changed to one
with a lower-risk profile (Masand & Mago 2005).
Lifestyle modification is considered first-line treatment
for metabolic anomalies and has been found to be effective
in halting the progression of metabolic syndrome (Ginsberg
2003; Sacks 2004). Lifestyle modification involves assess-
ing the person’s diet and nutritional status and exercise
regime, and making changes to influence weight reduction
and increase physical activity (Nutrition Australia 2002;
Ginsberg 2003; Diabetes Australia 2004b; Sacks 2004).
There are many weight loss programmes available, and
nurses can help guide the client to choose a reputable
group, for example, Diabetes Australia, the National Heart
Foundation, Nutrition Australia or local dieticians (Evans
 
et al
 
. 2005). A recent study found that individual nutrition
education from a dietician alone can minimize weight gain
for the person commenced on olanzapine (Evans 
 
et al
 
.
2005). Table 2 outlines steps that the client can take to
assist in reducing the development of metabolic syndrome.
 
Table 1 
 
Clinical indicators of metabolic syndrome
Waist circumference
Women
 
>
 
88 cm
Men 
 
>
 
102 cm
Serum triglycerides
 
≥
 
150 mg/dL
HDL cholesterol
Women
 
<
 
50 mg/dL
Men
 
<
 
40 mg/dL
Blood pressure
 
≥
 
130/
 
≥
 
85 mmHg
Fasting glucose
 
≥
 
100 mg/dL
 
Masand & Mago (2005).
HDL, high-density lipoprotein.
 
Table 2 
 
Steps to reduce the development of metabolic syndrome
Six steps to reduce metabolic syndrome
Increase activity level
Improve health through better eating habits
Lose weight
Quit smoking
Reduce stress levels
Take any medication prescribed
 
Nutrition Australia (2002).
 
Table 3 
 
Guidelines for practice
Guidelines for practice for the person who is taking second generation antipsychotics
Comprehensive baseline assessment, including:
• Physical examination
• Cardiac investigations
• Blood chemistries
• Weight
• Height
• Waist measurement
• Body mass index (BMI)
• Family history
• Personal history
• Monitoring of BP, BMI and waist circumference at 4, 8 and 12 weeks after commencing treatment is recommended then 3 monthly
(Baptista 
 
et al
 
. 2004; Masand & Mago 2005)
• If there are no signs or current risk factors for metabolic syndrome indicated that the nurse needs to continue regular monitoring of BP, waist 
circumference and educate the person re: diet and exercise (Wirshing 
 
et al
 
. 2003; Antai-Otong 2004; Gupta 2004; Lambert & Chapman 2004)
If there is evidence of early indicators (increased waist circumference and elevated blood pressure), there is a need to monitor:
• waist circumference every 3 months
• BP every 3 months
• BMI every 3 months (Wirshing 
 
et al
 
. 2003; Antai-Otong 2004; Gupta 2004; Lambert & Chapman 2004)
• Commence treatment, e.g. reduction of weight and an increase in physical activity (Wirshing 
 
et al
 
. 2003; Antai-Otong 2004)
• If there are three or more symptoms of metabolic syndrome need to commence treatment (e.g. reduction of weight, and an increase in physical
activity and medications Wirshing 
 
et al
 
. 2003; Antai-Otong 2004), ongoing monitoring and referral to a specialist
 
BP, blood pressure.
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Good early clinical indicators of metabolic syndrome
include an increase in waist circumference and elevated
blood pressure (Gupta 2004). When three or more of the
components of metabolic syndrome are present (i.e. weight
gain, increased blood pressure, raised triglycerides, lowered
HDL, and raised fasting glucose levels), there is a need for
active intervention (Wirshing 
 
et al
 
. 2003). First-line ther-
apy involves reduction of weight and an increase in phys-
ical activity (Wirshing 
 
et al
 
. 2003; Antai-Otong 2004).
Table 3 summarizes the guidelines for practice for mental
health nurses working with the person taking SGAs.
 
Conclusion
 
Metabolic syndrome is becoming increasingly prevalent in
at-risk populations, including clients treated with SGA
medication. Several explanations for the increase of this
syndrome in people with schizophrenia include hereditary
factors, the environment, lifestyle and drugs. Mental health
nurses need to consider their important role in the preven-
tion and ongoing management of people with this syn-
drome. To begin, mental health nurses must become aware
of the syndrome, its link to SGAs and its implications. The
benefits of increased awareness of metabolic syndrome for
mental health nurses are the early detection of symptoms
for clients and increased understanding of the need for
ongoing monitoring and treatment. Careful monitoring of
at-risk clients may help prevent the onset of metabolic syn-
drome or help prevent further deterioration of the client’s
physical health status. Nurses also have an important role
to play in educating clients about the potential for meta-
bolic syndrome and its link to SGAs. As a group with a
higher than average risk for diabetes, the client needs assis-
tance to weigh up the advantages and disadvantages of tak-
ing antipsychotic drugs, particularly the SGAs.
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